ArticleJournal of molecular neuroscience : MN2022
Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson's Disease.
Article in Journal of molecular neuroscience : MN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Ramadan fasting influences respiratory sarcopenia and plasma markers of neuromuscular junction health in older adults.European journal of applied physiology · 2026Article
- Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Plasma CAF22 Predicts Incident Freezing of Gait in Parkinson's Disease: A Prospective Cohort Study.Journal of molecular neuroscience : MN · 2026Article
- Smoking quitting promotes neuromuscular and cartilage recovery in knee osteoarthritis.European journal of applied physiology · 2026Article
- Associations between handgrip strength, motor tasks, and quality of life in older adults with osteoarthritis.European journal of applied physiology · 2026Article
- An exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.Aging clinical and experimental research · 2026Article
- Neuromuscular Junction as a Molecular Target in Sarcopenia: Mechanisms, Therapeutic Strategies, and Future Directions.Molecular diagnosis & therapy · 2026Review
- Effects of Ramadan fasting on physical capacity and plasma markers of neuromuscular junction degradation in older adult men.European journal of nutrition · 2026Article
- A machine learning pipeline identifies non-motor symptoms as key contributors to sarcopenia in Parkinson's disease.Clinical parkinsonism & related disorders · 2026Article
- Cross-sectional comparison of lower-limb muscle strength and contractile properties according to Parkinson's disease and sarcopenia status.Frontiers in medicine · 2026Article
- Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer.International journal of clinical oncology · 2025Article
- Neural Cues and Genomic Clues: NGS Insights into Neurogenic Sarcopenia and Muscle Atrophy.International journal of molecular sciences · 2025Review
- Alterations in the Myokine Concentrations in Relation to Sarcopenia and Sleep Disturbances: A Narrative Review.Journal of clinical medicine · 2025Review
- Review
- Analysis of the diagnostic accuracy of plasma sTNFr-2 concentrations in identifying sarcopenia in community-dwelling older women.Scientific reports · 2025Article
- Associations of plasma Neurofilament light chain with sarcopenia and physical capacity in patients with Alzheimer's diseases.Acta neurologica Belgica · 2025Observational
- The simple task of lifting five kilograms serves as a predictor of age-related disorders in old adults.Scientific reports · 2025Article
- Plasma brain-derived neurotrophic factor concentrations are elevated in community-dwelling adults with sarcopenia.Age and ageing · 2025Article
- Age, cancer, and the dual burden of cancer and doxorubicin in skeletal muscle wasting in female rats: which one to blame?Biogerontology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Patients with Parkinson's disease (PD) present with an advanced form of age-related muscle loss or sarcopenia. However, the search for a biomarker to accurately predict muscle loss in PD remains elusive. We evaluated the biomarkers of neuromuscular junction (NMJ) stability, including c-terminal agrin fragment-22 (CAF22), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) as predictors of muscle wasting and physical capacity in PD. Male, 63-78 years patients of PD, were investigated for physical capacity, handgrip strength (HGS), and circulating biomarkers at the diagnosis and follow-up during rehabilitation 6 months apart. Patients with PD presented with elevated CAF22 and reduced BDNF and GDNF levels, which were partially restored to normal levels with rehabilitation. All three biomarkers showed significant dynamic associations with HGS and indexes of sarcopenia. Logistic regression revealed that the combination of biomarkers levels into a cumulative risk score enhanced the diagnostic accuracy of sarcopenia. In brief, measurements of plasma BDNF, GDNF, and CAF22 may be helpful in timely diagnosis and/or evaluation of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.